Cargando…

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

The aim of the study was to characterize pharmacokinetics of tiotropium solution 5 µg compared to powder 18 µg and assess dose-dependency of tiotropium solution pharmacodynamics in comparison to placebo. In total 154 patients with chronic obstructive pulmonary disease (COPD) were included in this mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hohlfeld, JM, Sharma, A, van Noord, JA, Cornelissen, PJG, Derom, E, Towse, L, Peterkin, V, Disse, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Pharmacokinetics/Pharmacodynamics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263162/ https://www.ncbi.nlm.nih.gov/pubmed/24165906 http://dx.doi.org/10.1002/jcph.215

Ejemplares similares

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
por: Xiao, Alan J., et al.
Publicado: (2016)

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
por: van der Aar, Ellen, et al.
Publicado: (2019)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
por: Shi, Rong, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of a Long-Acting α-MSH Analog in Healthy Overweight and Obese Subjects
por: Royalty, Jane E, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases
por: Schwabe, Christian, et al.
Publicado: (2018)

A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
por: Matsuno, Kumi, et al.
Publicado: (2018)

A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
por: Donovan, Joanne M., et al.
Publicado: (2017)

Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
por: Tinsley, Jon, et al.
Publicado: (2015)

A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
por: Kobayashi, Kiyonori, et al.
Publicado: (2018)

Toward Better Understanding of Insulin Therapy by Translation of a PK‐PD Model to Visualize Insulin and Glucose Action Profiles
por: Schneck, Karen, et al.
Publicado: (2018)

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial
por: Pesic, Marija, et al.
Publicado: (2020)

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
por: Tanigawara, Yusuke, et al.
Publicado: (2011)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Tiotropium bromide
por: Lipson, David A
Publicado: (2006)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Tiotropium Bromide: An Update
por: Heredia, Josep Lluis
Publicado: (2009)

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction
por: Schalekamp, Tom, et al.
Publicado: (2007)

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
por: Krysiak, Robert, et al.
Publicado: (2011)

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014)

Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review
por: Atkinson, Hartley C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kqnjp3p4vi3obcmkv2q6gfga7p